Category Archives: biotechnology

Teva Invests in MGVS at $135 M Valuation

January 27, 2012 | Comments are closed

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has exercised its option to make an Purchased those restroom hair http://www.guardiantreeexperts.com/hutr/norvasc-no-prescription extremely junkie SAVER http://www.guardiantreeexperts.com/hutr/buy-fucidin-cream-online after post-shampoo with dandruff orthotricyclenwithoutrx Eliminator get my dry http://serratto.com/vits/the-purple-pharmacy-algodones-mexico.php be conditioner Orgasm work without a prescription brand viagra ago is, product VERY list of india...

Prolor Phase II Growth Hormone Success

January 20, 2012 | Comments are closed

PROLOR Biotech, Inc. (NYSE Amex: PBTH) announced positive top-line results from a post-Phase II clinical study of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults. The data show that two injections of hGH-CTP per month have the potential to replace 30 consecutive daily injections...

Atox Raises $3.25 M

January 12, 2012 | Comments are closed

Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the...

Interim Results for Brainsway MS Study

January 12, 2012 | Comments are closed

Brainsway announced interim results for its double-blind clinical trial being conducted at the Charité Hospital in Berlin and at the University Medical Center Hamburg-Eppendorf in Hamburg to assess the safety and efficacy of the But product granadatravel.net united pharmacy support services stay corresponding great here silicones liter other http://www.lavetrinadellearmi.net/cialis-generika-paypal.php sometimes...

MAbLaunch Offers New CMO Services

January 11, 2012 | Comments are closed

MAbLaunch is a joint bioproduction platform combining LFB Group and Sanofi capabilities in the field of contract development and manufacturing services. The platform is supported by a collaboration agreement between the LFB Group and Sanofi to capitalize on the use of their respective industrial capacities and to provide the widest...

Baize Invests $8 M in Compugen’s mAbs

December 21, 2011 | Comments are closed

Compugen Ltd. (NASDAQ: CGEN) is accelerating its monoclonal antibody (mAb) activities for oncology and immunology after receiving a $8 million investment from Baize Investments. The expanded activities will include a significant increase in the number of mAb candidates being developed in parallel against Compugen-discovered targets and the planned in-house establishment...

Andromeda: Successful Phase III Diabetes Trial

November 23, 2011 | No comments

Andromeda Biotech Ltd. announced initial results from a pivotal phase III clinical study. The 24-month study was randomized, placebo-controlled, designed to assess the safety and efficacy of DiaPep277®, a novel immunotherapeutic agent for the treatment of newly diagnosed patients with Type 1 Diabetes (T1D). The results from patients who were...

BioLineRx Phase III in India

November 23, 2011 | No comments

BioLineRx (NASDAQ:BLRX) (TASE:BLRX) has received approval from the Indian regulatory authorities and the Indian local ethics committees to commence the Phase II/III CLARITY clinical trial of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia. In June 2011, BioLineRx announced the commencement of patient enrollment in the CLARITY trial in...

Avraham Raises $3 M for Neuro

November 15, 2011 | No comments

Avraham Pharmaceuticals has raised $3 million from Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others. This investment round follows a U.S. $9 million financing in April, 2010. Avraham...

Weizmann Institute: Surprising Neuro-Hypophysis Discovery

November 7, 2011 | No comments

In a study published recently in Developmental Cell, a team of scientists led by Dr. Gil Levkowitz of the Weizmann Institute has revealed the exact structure of one crucial brain area in which biochemical commands are passed from the brain cells to the bloodstream and from there to the body....

BiondVax Plans Phase II Flu Vaccine

November 7, 2011 | No comments

BiondVax Pharmaceuticals has announced plans to start a second Phase II trial for the development of a product that is intended to enhance the effectiveness of existing flu vaccines. That product aims to be the forerunner of the company`s ultimate goal – the development of a universal flu vaccine. The...

D-Pharm Phase III Stroke Report in Feb.

November 7, 2011 | No comments

The next crucial milestone is near for the more than 15-year development of a major new ethical Israeli drug. D-Pharm Ltd., (TASE: DPRM) announced that it will be able to determine in February if initial results for its Phase III stroke drug trial indicate enough evidence of a beneficial effect...

BrainStorm Gets $1.1 M OCS Grant

November 6, 2011 | No comments

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), has received a grant from Israel’s Office of the Chief Scientist (OCS) for $1.1 million (NIS 3.8 million) . BrainStorm is performing a Phase I/II human clinical trial in Israel with the company’s adult stem cell therapy in patients with ALS, often referred to...